Garg Ishu, Kumar Harish, Verma Madhu, Chauhan Iti, Panwar Vishal
Sardar Bhagwan Singh Post Graduate Institute of Biomedical Sciences and Research, Balawala, Dehradun, Uttarakhand, 248161, India.
ITS College of Pharmacy, Ghaziabad, Muradnagar, India.
Cardiovasc Hematol Disord Drug Targets. 2025;25(2):98-118. doi: 10.2174/011871529X361429250215190129.
The past decade has appreciated personalized medicine as a novel medical approach that deals with all practices that are tailored to individual patients. Personalized treatment or personalized cardiology for cardiovascular disorders is an emerging medicine system for related patients. Personalized cardiology is solely based on genomics and proteomics; molecular diagnostics and biomarkers of the cardiovascular system link diagnosis with therapy. Bioinformatics is useful in CVD risk stratification and might improve risk-estimating algorithms. Personalized cardiology involves 3D printing, pharmacotherapy, surgery, lifestyle modifications, and combinations thereof. Understanding the pathology of CVD and identifying causative factors at the individual level can provide opportunities for developing personalized medicine. Since it offers novel avenues for diagnosing, preventing, and treating CVD, molecular genetics has made a substantial contribution to the field of molecular cardiology. Nonetheless, there are still a lot of obstacles to overcome from the standpoints of science and policy. These obstacles can be avoided using evidence-based procedures, clinical applications, biomarker-based detection techniques, comprehensive concepts, and understanding. Targeted therapies may be developed as a result of improved disease classification and a better knowledge of the individual differences in pathology. Cardiovascular disorders, like hypertension, angina, or ischemic heart, a condition of reduced blood flow to the heart, coronary artery disease or damaged blood vessels, myocardial infarction or resisted blood flow to the myocardium, and cardiac arrhythmia or irregular cardiac cycles are the primary targets for personalized cardiology. The current review discusses various parameters for personalizing the treatment of cardiovascular disorders.
在过去十年中，个性化医疗已成为一种新颖的医疗方法，涵盖了所有针对个体患者量身定制的医疗实践。针对心血管疾病的个性化治疗或个性化心脏病学是一种针对相关患者的新兴医疗体系。个性化心脏病学完全基于基因组学和蛋白质组学；心血管系统的分子诊断和生物标志物将诊断与治疗联系起来。生物信息学在心血管疾病风险分层中很有用，可能会改进风险评估算法。个性化心脏病学涉及3D打印、药物治疗、手术、生活方式改变及其组合。了解心血管疾病的病理学并在个体层面识别致病因素可为开发个性化医疗提供机会。由于分子遗传学为心血管疾病的诊断、预防和治疗提供了新途径，因此它对分子心脏病学领域做出了重大贡献。尽管如此，从科学和政策的角度来看，仍有许多障碍需要克服。可以通过基于证据的程序、临床应用、基于生物标志物的检测技术、全面的概念和理解来避免这些障碍。由于疾病分类的改进和对个体病理差异的更好了解，可能会开发出靶向治疗方法。心血管疾病，如高血压、心绞痛或缺血性心脏病（一种心脏血流减少的病症）、冠状动脉疾病或血管受损、心肌梗死或心肌血流受阻以及心律失常或心脏周期不规则，是个性化心脏病学的主要目标。本综述讨论了个性化治疗心血管疾病的各种参数。
